Serum Intact Parathyroid Hormone (iPTH) at Chughtai Lab

Serum Intact Parathyroid Hormone (iPTH) at Chughtai Lab

Serum Intact Parathyroid Hormone (iPTH) is a highly specialized diagnostic blood test designed to measure the concentration of active parathyroid hormone in the systemic circulation. Secreted by the four small parathyroid glands situated posterior to the thyroid gland in the neck, parathyroid hormone is the primary endocrine regulator of calcium, phosphorus, and active vitamin D homeostasis. The term “intact” refers specifically to the biologically active, full-length 84-amino-acid polypeptide chain. Measuring this intact form is clinically superior to evaluating hormone fragments, as it provides an accurate, real-time reflection of parathyroid gland secretory activity. Chughtai Lab, Pakistan’s leading diagnostic network, performs this critical investigation using advanced automated chemiluminescent immunoassay (CLIA) technology, ensuring exceptional analytical sensitivity and clinical precision for patients nationwide.

The endocrine regulation of calcium is governed by a highly sensitive negative feedback loop. When ionized calcium levels in the blood decrease, calcium-sensing receptors (CaSR) on the surface of parathyroid cells detect this change, rapidly triggering the synthesis and secretion of PTH. The hormone exerts its physiological effects on three primary target organs: bones, kidneys, and the gastrointestinal tract. In the skeletal system, PTH stimulates osteoclast activity, promoting bone resorption and the release of calcium and phosphate into the bloodstream. In the kidneys, PTH enhances distal renal tubule calcium reabsorption, inhibits proximal tubule phosphate reabsorption, and upregulates the 1-alpha-hydroxylase enzyme. This enzyme converts inactive vitamin D into its active form, calcitriol, which subsequently enhances dietary calcium absorption in the small intestine. Once systemic calcium levels return to normal, the feedback loop suppresses further PTH secretion. Disruptions in this regulatory pathway can lead to severe metabolic bone diseases, renal complications, and neuromuscular dysfunction, highlighting the diagnostic importance of the Serum Intact Parathyroid Hormone (iPTH) test at Chughtai Lab.

Clinical Procedure: What to Expect

Patient Preparation

Achieving accurate and clinically reliable results for the Serum Intact Parathyroid Hormone (iPTH) test requires strict adherence to patient preparation guidelines. Because PTH levels are physiologically linked to other metabolic markers, the following steps must be followed:

• Fasting Requirements: Patients are strongly advised to fast for 8 to 12 hours prior to sample collection. While fasting is not strictly mandatory for isolating the iPTH hormone itself, it is highly recommended because serum calcium, phosphorus, and renal function markers are almost always evaluated concurrently to provide a comprehensive clinical assessment.
• Diurnal Variation and Timing: A morning blood sample, preferably collected between 8:00 AM and 10:00 AM, is the clinical standard. Parathyroid hormone levels exhibit a natural diurnal rhythm, typically peaking during the early morning hours. Consistent morning collection ensures standardized results.
• Biotin Avoidance: Patients must strictly avoid taking biotin (Vitamin B7) supplements for at least 48 to 72 hours before the test. Biotin is a common component in hair, skin, and nail supplements. High circulating levels of biotin can severely interfere with the streptavidin-biotin binding systems utilized in modern automated immunoassay platforms, leading to falsely suppressed or falsely elevated iPTH measurements.
• Medication Review: It is essential to inform the ordering physician and laboratory staff of all current medications. Certain drugs, including lithium, thiazide diuretics, calcium supplements, and active vitamin D analogs, can alter baseline parathyroid hormone levels and must be clinically accounted for during result interpretation.

During the Procedure

The Serum Intact Parathyroid Hormone (iPTH) test is a routine, minimally invasive venipuncture procedure performed by highly trained phlebotomists at Chughtai Lab. The process is designed to maximize patient comfort and preserve sample integrity:

• Patient Identification and Setup: Upon arrival, the patient’s identity and pre-test preparation (such as fasting status and biotin avoidance) are verified. The patient is seated comfortably in a blood collection chair.
• Venipuncture: The phlebotomist selects a suitable vein, typically in the antecubital fossa of the arm, and cleanses the area with an antiseptic alcohol swab. A sterile tourniquet is applied briefly to engorge the vein. A sterile, single-use needle is inserted to draw the blood sample.
• Sample Collection: Blood is collected into a specialized tube, typically an EDTA plasma tube or a serum separator tube (SST). Because intact PTH is highly unstable and prone to rapid enzymatic degradation at room temperature, Chughtai Lab enforces strict pre-analytical protocols, including immediate cold-chain management and rapid centrifugation to preserve hormone integrity.
• Post-Collection Care: The needle is removed, and gentle pressure is applied to the puncture site with a sterile cotton swab, followed by a small adhesive bandage. The entire process takes less than five minutes and is associated with minimal discomfort, typically described as a brief pinch. Patients can immediately resume their daily activities.

When is a Serum Intact Parathyroid Hormone (iPTH) Performed?

Evaluation of Unexplained Hypercalcemia

When routine biochemistry panels reveal elevated serum calcium levels, physicians request an iPTH test to identify the underlying cause. Hypercalcemia can be parathyroid-dependent or parathyroid-independent. An elevated or inappropriately normal iPTH level in the presence of high calcium points directly to primary hyperparathyroidism, usually caused by a benign parathyroid adenoma. Conversely, a suppressed iPTH level indicates that the hypercalcemia is driven by non-parathyroid mechanisms, such as malignancy, sarcoidosis, or vitamin D toxicity, prompting further targeted diagnostic investigations.

Investigation of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

Patients with chronic kidney disease (CKD) require regular monitoring of iPTH levels as part of their renal care. As kidney function declines, the body loses the ability to excrete phosphorus and synthesize active vitamin D. This leads to hyperphosphatemia and hypocalcemia, which continuously stimulate the parathyroid glands, resulting in secondary hyperparathyroidism. Monitoring iPTH helps nephrologists assess bone turnover rates and guide medical therapies, including phosphate binders, vitamin D receptor activators, and calcimimetics, to prevent renal osteodystrophy and cardiovascular calcification.

Diagnosis and Monitoring of Hypocalcemia

Hypocalcemia, which can present with symptoms like muscle cramps, paresthesia, and neuromuscular irritability, requires immediate diagnostic evaluation. Measuring iPTH helps differentiate between primary hypoparathyroidism (where iPTH is low or undetectable due to gland damage or autoimmune destruction) and secondary hyperparathyroidism (where iPTH is elevated as a normal physiological response to low calcium caused by severe vitamin D deficiency or intestinal malabsorption).

Assessment of Metabolic Bone Diseases and Osteoporosis

Unexplained bone loss, recurrent low-impact fractures, or severe osteoporosis warrant an iPTH evaluation. Primary hyperparathyroidism can remain clinically silent for years, gradually depleting calcium from the skeletal system to maintain blood levels. By measuring iPTH, endocrinologists can identify silent parathyroid disorders, assess bone remodeling activity, and formulate targeted treatment plans to restore bone mineral density and reduce future fracture risks.

Preoperative and Postoperative Management in Parathyroid Surgery

For patients undergoing parathyroidectomy to treat hyperparathyroidism, the iPTH test is an indispensable perioperative tool. Surgeons utilize rapid intraoperative iPTH assays to confirm the successful removal of hyperfunctioning parathyroid tissue. Because the half-life of intact PTH is extremely short (approximately 3 to 5 minutes), a significant drop in iPTH levels (greater than 50% from baseline) within 10 minutes of tissue resection confirms that the offending adenoma has been successfully excised. Postoperatively, serial iPTH measurements help monitor gland recovery and prevent transient or permanent hypocalcemia.

What Does a Serum Intact Parathyroid Hormone (iPTH) Detect?

The Serum Intact Parathyroid Hormone (iPTH) test, when interpreted alongside serum calcium and phosphorus levels, can detect a wide spectrum of endocrine, renal, and bone disorders. Specifically, it can detect:

• Primary hyperparathyroidism caused by a single benign parathyroid adenoma.
• Primary hyperparathyroidism due to multiglandular parathyroid hyperplasia.
• Rare parathyroid carcinoma presenting with extremely high iPTH and severe hypercalcemia.
• Secondary hyperparathyroidism secondary to chronic kidney disease (CKD).
• Secondary hyperparathyroidism driven by nutritional Vitamin D deficiency.
• Secondary hyperparathyroidism caused by calcium malabsorption in celiac disease or Crohn’s disease.
• Tertiary hyperparathyroidism, characterized by autonomous PTH secretion after prolonged secondary hyperparathyroidism.
• Post-surgical hypoparathyroidism resulting from accidental damage or removal of parathyroid glands during thyroidectomy.
• Autoimmune hypoparathyroidism, where the body’s immune system attacks the parathyroid glands.
• Congenital hypoparathyroidism associated with genetic conditions like DiGeorge syndrome.
• Pseudohypoparathyroidism, a rare genetic disorder characterized by target organ resistance to PTH.
• Pseudopseudohypoparathyroidism, presenting with physical features of osteodystrophy but normal hormone levels.
• Hypercalcemia of malignancy, where tumor-secreted PTHrP suppresses endogenous iPTH levels.
• Vitamin D toxicity, leading to hypercalcemia and subsequent physiological suppression of iPTH.
• Milk-alkali syndrome, caused by excessive ingestion of calcium and absorbable alkali, suppressing iPTH.
• Sarcoidosis and other granulomatous diseases causing extra-renal vitamin D activation and suppressed iPTH.
• Familial hypocalciuric hypercalcemia (FHH), a benign genetic condition presenting with mild hypercalcemia and normal-to-high iPTH.
• Severe hypomagnesemia, which impairs both PTH secretion and peripheral tissue responsiveness to PTH.
• Hypermagnesemia, which can suppress PTH secretion by activating calcium-sensing receptors.
• Adrenal insufficiency-associated hypercalcemia with suppressed iPTH levels.
• Immobilization-induced hypercalcemia, leading to suppressed parathyroid gland activity.
• Thiazide diuretic-induced hypercalcemia with mild alterations in parathyroid hormone dynamics.
• Lithium-induced hyperparathyroidism, where lithium shifts the set-point of calcium-sensing receptors.
• Hungry bone syndrome, characterized by rapid skeletal uptake of calcium and reactive iPTH elevation post-parathyroidectomy.
• Renal osteodystrophy subtypes, distinguishing high-turnover osteitis fibrosa cystica from low-turnover adynamic bone disease.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that timely diagnostic insights are critical for effective clinical decision-making. The Serum Intact Parathyroid Hormone (iPTH) test is processed using advanced automated analyzers under strict quality control protocols. The turnaround time (TAT) for the iPTH test at Chughtai Lab is typically within 24 hours from the time of sample collection. Patients and referring physicians can access reports seamlessly through multiple digital channels. Once the results are verified by a consultant pathologist, a secure PDF report is made available on the official Chughtai Lab website portal and the Chughtai Lab mobile application. Additionally, patients can opt to receive their reports via WhatsApp or collect a printed copy from any Chughtai Lab collection center across Pakistan.

Serum Intact Parathyroid Hormone (iPTH) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum Intact PTH (iPTH)	15 – 65 pg/mL	Elevated (>65 pg/mL) in hyperparathyroidism or renal failure; Suppressed (<15 pg/mL) in hypoparathyroidism or non-parathyroid hypercalcemia.
Serum Calcium (Total)	8.5 – 10.2 mg/dL	Elevated in primary hyperparathyroidism or malignancy; Decreased in hypoparathyroidism or severe vitamin D deficiency.
Serum Phosphorus	2.5 – 4.5 mg/dL	Decreased in primary hyperparathyroidism; Elevated in renal failure or hypoparathyroidism.
25-Hydroxyvitamin D	30 – 100 ng/mL	Decreased (<20 ng/mL) indicating deficiency, which can trigger secondary hyperparathyroidism; Elevated in vitamin D toxicity.
Serum Creatinine	0.6 – 1.2 mg/dL	Elevated in renal impairment, indicating potential secondary hyperparathyroidism.
Serum Magnesium	1.7 – 2.2 mg/dL	Severely decreased (<1.0 mg/dL) impairing PTH secretion and action; Elevated suppressing PTH.
Alkaline Phosphatase (ALP)	44 – 147 IU/L	Elevated in high-turnover bone diseases, primary hyperparathyroidism, or renal osteodystrophy.
24-Hour Urine Calcium	100 – 300 mg/24 hours	Elevated in primary hyperparathyroidism; Decreased (<100 mg/24 hours) in familial hypocalciuric hypercalcemia (FHH) or hypoparathyroidism.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum Intact Parathyroid Hormone (iPTH)?

• ISO 15189 Certified Laboratories: Chughtai Lab maintains international standards of quality, ensuring highly accurate and reproducible diagnostic results.
• Advanced Immunoassay Technology: We utilize state-of-the-art automated Chemiluminescent Immunoassay (CLIA) platforms for precise hormone measurements.
• Expert Pathologist Supervision: All specialized endocrine tests are supervised and verified by highly qualified Consultant Pathologists and Clinical Chemists.
• Convenient Home Sample Collection: Patients can avail of our professional home sampling services across major cities in Pakistan, bringing quality healthcare to their doorstep.
• Extensive Nationwide Network: With over 300 collection centers across Pakistan, accessing world-class diagnostic services is convenient and hassle-free.
• Rapid Turnaround Time: Our optimized laboratory workflows ensure that iPTH test reports are delivered within 24 hours of sample receipt.
• Seamless Digital Report Access: Patients can view, download, and share reports via our user-friendly mobile app, official website portal, or automated WhatsApp service.
• Rigorous Quality Control: Chughtai Lab participates in international External Quality Assessment Schemes (EQAS) to maintain the highest levels of analytical accuracy.